1. Pink Sheet

Dengvaxia’s Restrictive Indication Will Make Immunization Recommendations Difficult, ACIP Members Say

 
• By Sue Sutter

The need to screen individuals in dengue-endemic areas for prior infection before administering Sanofi’s vaccine will be difficult to operationalize, particularly in the absence of a reliable and rapid diagnostic, experts say; Advisory Committee on Immunization Practices working group aims for full committee vote on use recommendations in February 2020.

Mosquito bites hand concept, Mosquito sucking blood on skin of hand on blurred green forest background For children being bitten by mosquitoes is a scary thing. Dengue fever or related illness. - Image
ACIP has a difficult task ahead of it in making immunization recommendations targeting the mosquito-borne dengue virus. • Source: Shutterstock

The challenges of developing and implementing an immunization recommendation for Sanofi’s dengue vaccine Dengvaxia were readily apparent at the recent meeting of the US Advisory Committee for Immunization Practices.

Even though the Centers for Disease Control and Prevention panel is not expected to vote on a use recommendation until early 2020, preliminary discussion suggests committee members will struggle with concerns about how to operationalize any

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.